Gilead Sciences (GILD) Tops Q1 EPS by 31c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Gilead Sciences Announces First Quarter 2022 Financial Results
April 28, 2022 4:02 PM EDTBiktarvy Sales Increased 18% Year-Over-Year to $2.2 billion
Oncology Sales Increased 60% Year-Over-Year to $420 million
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter of 2022.
Gileads performance in the first quarter reflects the strength and diversity of our business with both our HIV and oncology therapies contributing to year-over-year growth, said Daniel ODay, Chairman and Chief Executive Officer, Gilead Sciences. Biktarvy delivered strong 18% year-over-year revenue growth, and oncology sales increased by 60% year-over-year,... More
